--- title: "Single-arm phase II trials with binary endpoints" author: "Jiangyan Zhao and Rongji Mu" output: rmarkdown::html_vignette: toc: true vignette: > %\VignetteIndexEntry{Single-arm phase II trials with binary endpoints} %\VignetteEngine{knitr::rmarkdown} %\VignetteEncoding{UTF-8} --- ```{r setup, include=FALSE} knitr::opts_chunk$set(collapse = TRUE, comment = "#>") library(BayesianTrial) ``` ## Clinical question and trial design Consider a hypothetical single-arm phase II trial evaluating the objective response rate (ORR) of a new treatment. The historical ORR is 20%, while 40% is considered a promising response rate. The study uses a binary endpoint (response or no response) and a Beta(0.2, 0.8) prior. The trial plans one interim analysis after 20 patients, with a maximum sample size of 40. Efficacy and futility decisions are based on the posterior probability that the ORR exceeds the historical rate of 20%: | Analysis | Decision rule | |:--|:--| | Interim | Stop for efficacy if the posterior probability is > 0.98 | | Interim | Stop for futility if the posterior probability is <= 0.50 | | Interim | Otherwise, continue enrollment | | Final, if continued | Declare success if the posterior probability is > 0.95 | These sample sizes and thresholds are illustrative. In practice, they should be specified before enrollment and assessed against the trial's desired type I error rate and power. ## Evaluate the design before enrollment Use `oc_singlearm_binary()` to estimate the operating characteristics of this two-stage design. We consider a true ORR of 20% for the null scenario and 40% for the alternative scenario. ```{r operating-characteristics} true_rates <- c(0.20, 0.40) oc_results <- lapply(true_rates, function(theta) { oc_singlearm_binary( theta_true = theta, n_current = 20, N_total = 40, alpha0 = 0.2, beta0 = 0.8, theta0_null = 0.20, gamma_early = 0.98, gamma_futility = 0.50, gamma_final = 0.95, ntrial = 10000, seed = 666 ) }) oc_table <- data.frame( true_ORR = true_rates, do.call(rbind, lapply(oc_results, unlist)), row.names = NULL ) knitr::kable(oc_table, digits = 3) ``` The `power_null_post` column gives the overall probability of declaring the trial successful, including early efficacy stopping. It estimates the **type I error rate** when the true ORR is 20%, and **power** when the true ORR is 40%. The two remaining columns give the probabilities of stopping early for futility or efficacy. The 40% rate is used here to evaluate power, **not** as an additional requirement for declaring trial success. If the operating characteristics do not meet the design targets, revise the sample sizes or thresholds and evaluate the design again. The function evaluates specified designs; it does not calibrate them automatically. ## Analyze the interim results Suppose 9 of the first 20 patients respond. At the interim analysis, calculate the posterior probability that the ORR exceeds the historical reference rate of 20%: ```{r interim-posterior} posterior <- posterior_predictive_singlearm_binary( x_obs = 9, n_current = 20, N_total = 40, alpha0 = 0.2, beta0 = 0.8, theta0_null = 0.20 ) posterior$p_null ``` The posterior distribution is Beta(9.2, 11.8), and the probability of exceeding 20% is approximately 0.992. Apply the prespecified interim stopping rules to the observed data: ```{r interim-decision} decision <- if (posterior$p_null > 0.98) { "Stop for efficacy" } else if (posterior$p_null <= 0.50) { "Stop for futility" } else { "Continue to the final analysis" } decision ``` The posterior probability exceeds the efficacy stopping threshold of 0.98, so the trial stops early for efficacy under this design. For trials that continue, final success requires the posterior probability of exceeding 20% to be greater than 0.95. ## Predictive probability if enrollment continues For illustration, we also assess the probability of meeting the final success criterion **if the trial were to continue to 40 evaluable patients**, despite meeting the early efficacy stopping rule: ```{r interim-predictive} predictive <- posterior_predictive_singlearm_binary( x_obs = 9, n_current = 20, N_total = 40, alpha0 = 0.2, beta0 = 0.8, theta0_null = 0.20, gamma_final = 0.95, type = "predictive", S = 10000, seed = 666 ) predictive$ppos_null ``` Here, `ppos_null` is the posterior predictive probability that the final posterior probability will exceed 0.95. This is a supplementary assessment and does not determine stopping in the current design. The function defaults to `type = "posterior"`; setting `type = "both"` returns posterior summaries and predictive probabilities together. ## Additional clinical-target assessment The predictive function also reports `ppos_clin`, the probability of meeting a separate posterior criterion for a clinically relevant ORR (`theta0_clin`, default 0.40). Its final posterior threshold is `gamma_clin_final` (default 0.90). This output can be used as an additional summary but is **not** included in the success and stopping rules evaluated by `oc_singlearm_binary()`. To adapt the example to another study, specify its historical response rate, prior, interim and maximum sample sizes, and decision thresholds. Reassess operating characteristics before using the design in a trial.